Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 326,887
  • Shares Outstanding, K 43,760
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,670 K
  • 36-Month Beta 2.13
  • Price/Sales 68.24
  • Price/Cash Flow N/A
  • Price/Book 148.19

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.91 +26.40%
on 09/08/17
7.79 -4.11%
on 09/21/17
+1.14 (+18.01%)
since 08/22/17
3-Month
5.00 +49.40%
on 06/27/17
8.29 -9.89%
on 07/27/17
+2.34 (+45.61%)
since 06/22/17
52-Week
1.15 +549.57%
on 11/09/16
8.29 -9.89%
on 07/27/17
+5.55 (+289.06%)
since 09/22/16

Most Recent Stories

More News
CymaBay Therapeutics to Present at Two Investor Conferences

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that...

CBAY : 7.47 (-1.19%)
CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need today announced that the European...

CBAY : 7.47 (-1.19%)
Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season

CymaBay Therapeutics (CBAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

CBAY : 7.47 (-1.19%)
Breakfast Technical Briefing on Biotech Stocks -- CytRx, Aeterna Zentaris, Capricor Therapeutics, and Cymabay Therapeutics

If you want a Stock Review on CYTR, AEZS, CAPR, or CBAY then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. In a note on Tuesday, July 11th, 2017,...

AEZS : 2.13 (+1.43%)
CBAY : 7.47 (-1.19%)
CYTR : 0.43 (-1.38%)
CAPR : 2.14 (+7.00%)
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the closing...

CBAY : 7.47 (-1.19%)
Cymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2%

Cymabay Therapeutics, Inc. (CBAY) moved big last session, as its shares rose over 6% on the day.

CBAY : 7.47 (-1.19%)
ANTM : 182.86 (-0.35%)
CymaBay Announces Proposed Public Offering of Common Stock

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it intends...

CBAY : 7.47 (-1.19%)
CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

-- Strong reduction in alkaline phosphatase of 39% (5 mg) and 45% (10 mg) at week 12

CBAY : 7.47 (-1.19%)
Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options

Investors need to pay close attention to Cymabay Therapeutics (CBAY) stock based on the movements in the options market lately.

CBAY : 7.47 (-1.19%)
New Analyst Coverage Make These 5 Stocks Worth a Bet

Most investors depend on analysts' research before taking decisions as they fear that lack of information might trigger inefficiencies. Here, analysts play a vital intermediary role with their extensive...

KIN : 7.40 (+0.68%)
CBAY : 7.47 (-1.19%)
DIOD : 28.81 (+1.27%)
INSW : 19.92 (+3.37%)
CUTR : 39.85 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Support & Resistance

2nd Resistance Point 7.87
1st Resistance Point 7.67
Last Price 7.47
1st Support Level 7.34
2nd Support Level 7.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.